COMMUNIQUÉS West-GlobeNewswire

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29/01/2024
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia ® in healthy adult subjects, met its primary endpoints Prolia ® and Xgeva ® (denosumab) are indicated for the [...]
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
29/01/2024
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of [...]
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
29/01/2024
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une nouvelle méthode [...]
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
29/01/2024
PRESS RELEASE Acceptance and filing review is a first step in the PMA review process Indicates PMA application is sufficiently complete for in-depth review Received in advance of anticipated timing Ghent, Belgium – 29 [...]
Philips delivers strong full-year results; agrees with FDA on terms of consent decree focused on Philips Respironics in the US
29/01/2024
January 29, 2024 Delivers strong sales growth, improved profitability, and strong cash flow in 2023 through solid execution of first year of 2023-2025 plan Agrees with FDA on terms of consent decree focused on Philips [...]
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies
29/01/2024
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal ® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies Phase 1b open label trial confirms safety and tolerability of 120 mg and 200 mg [...]
Sirona Biochem Initiates Private Placement
27/01/2024
VANCOUVER, British Columbia, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF) (the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units [...]
Vision Sensing Acquisition Corp. Responds to NASDAQ Letter and Hopeful of Expedient Resolution
26/01/2024
NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ” or “ VSAC ”), a special purpose acquisition company, issues an update regarding the previously [...]
Daré Bioscience Announces Executive Team and Board of Directors Changes
26/01/2024
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial [...]
BrightSpring Celebrates First Day of Trading on Nasdaq
26/01/2024
Will Make $100 Million Equity Grant to 20,000 Employees LOUISVILLE, Ky., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) today marked its first day [...]
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
26/01/2024
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical [...]
NADP and ADA Achieve Loss Ratio Compromise at NCOIL
26/01/2024
Model legislation offers middle ground solution on loss ratios DALLAS, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The National Association of Dental Plans (NADP) has successfully negotiated with the American Dental Association ( [...]
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26/01/2024
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS [...]
AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des Médicaments
26/01/2024
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AUPRÈS DE L'AGENCE EUROPÉENNE DES MÉDICAMENTS LA DÉCISION DE L' [...]
Zealand Pharma major shareholder announcement: Van Herk Investments
26/01/2024
Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a [...]
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
26/01/2024
HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
26/01/2024
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation [...]
GRI Bio Announces Reverse Stock Split
26/01/2024
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a [...]
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26/01/2024
SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated [...]

Pages